Four principal molecular subtypes—luminal A, luminal B, HER2-enriched, and triple-negative breast cancer (TNBC)—differ in receptor expression and proliferation markers, which directly influence prognosis and treatment strategies [12,13,14,15,16,17]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.